Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

Considering dual biologic therapy for psoriasis or eczema? Get a firsthand account of navigating insurance, potential side effects, and treatment outcomes.

Child mortality has been halved in the last 25 years. Building on this progress, new innovations in immunization are working ...

Children were randomized to receive a subcutaneous injection of dupilumab or placebo in addition to their standard therapy every two weeks for a year. Neither investigators nor participants knew who ...

--Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Commission has approved Dupixent ® to treat eosinophilic esophagitis in children as young as 1 year of age. Dupixent ...

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis ...

DUPIXENT ® was first approved in Canada in 2017 for the treatment of adults with moderate-to-severe atopic dermatitis. DUPIXENT ® has since been approved for the treatment of adolescents, children and ...

The trial found that a higher-exposure dupilumab regimen improved key secondary endpoints in children.

There were significant differences in percentages of children with eosinophilic esophagitis who experienced histologic remission with dupilumab compared with placebo, according to a study ...